Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 252Breast Neoplasms 197Glioblastoma 196Lung Neoplasms 195Head and Neck Neoplasms 176Squamous Cell Carcinoma of Head and Neck 166Prostatic Neoplasms 164Lymphoma 152Rectal Neoplasms 132Central Nervous System Neoplasms 119Esophageal Neoplasms 117Leukemia 111Brain Neoplasms 100Pancreatic Neoplasms 95Precursor Cell Lymphoblastic Leukemia-Lymphoma 93Gliosarcoma 86Esophageal Squamous Cell Carcinoma 83Lymphoma, Follicular 81Sarcoma 80Lymphoma, Large B-Cell, Diffuse 80Uterine Cervical Neoplasms 76Lymphoma, Non-Hodgkin 75Hodgkin Disease 73Neoplasms 68Burkitt Lymphoma 67Leukemia, Lymphocytic, Chronic, B-Cell 63Colorectal Neoplasms 63Glioma 61Astrocytoma 60Lymphoma, Large-Cell, Immunoblastic 58

Interventions

tazemetostat 1osimertinib 1itacitinib 1Radiotherapy 1Lovastatin 1INCB039110 1AZD1390 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Inhibition, Psychological × Radiotherapy × Clear all
NCT03423628 2025-12-22

A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer

AstraZeneca

Phase 1 Recruiting
180 enrolled
CNS

Brain Neoplasms, Glioblastoma, Inhibition, Psychological, Meningeal Neoplasms, Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡